STERIS - STE Stock Forecast, Price & News

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

STERIS Stock Performance

NYSE:STE traded down $1.49 on Tuesday, hitting $212.47. 282,462 shares of the stock traded hands, compared to its average volume of 489,529. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.35 and a current ratio of 2.03. The business's fifty day moving average is $210.64 and its two-hundred day moving average is $224.64. STERIS has a 12 month low of $192.40 and a 12 month high of $255.93. The firm has a market capitalization of $21.25 billion, a price-to-earnings ratio of 56.96 and a beta of 0.71.

STERIS Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 23rd. Stockholders of record on Wednesday, September 7th will be paid a dividend of $0.47 per share. This is an increase from STERIS's previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Tuesday, September 6th. This represents a $1.88 annualized dividend and a dividend yield of 0.88%. STERIS's dividend payout ratio is presently 46.11%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on STE shares. TheStreet raised shares of STERIS from a "c+" rating to a "b" rating in a research report on Tuesday, August 2nd. JMP Securities dropped their target price on shares of STERIS from $270.00 to $250.00 in a research report on Thursday, August 4th. StockNews.com raised STERIS from a "hold" rating to a "buy" rating in a report on Thursday, August 11th. Needham & Company LLC dropped their price target on STERIS from $248.00 to $237.00 and set a "buy" rating on the stock in a report on Thursday, August 4th. Finally, KeyCorp reduced their price objective on STERIS from $256.00 to $240.00 and set an "overweight" rating for the company in a research note on Thursday, August 4th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, STERIS presently has a consensus rating of "Buy" and a consensus target price of $252.00.

Insider Buying and Selling

In other STERIS news, VP John Adam Zangerle sold 2,659 shares of the stock in a transaction dated Wednesday, June 15th. The shares were sold at an average price of $205.31, for a total transaction of $545,919.29. Following the completion of the transaction, the vice president now owns 27,936 shares in the company, valued at $5,735,540.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.95% of the stock is currently owned by insiders.